| Particulars (Rupees in Crores.) | Mar-2025 | Dec-2024 | Sept-2024 | Jun-2024 | Mar-2024 |
|---|---|---|---|---|---|
Gross Sales | 12,815.58 | 13,436.94 | 13,264.22 | 12,524.51 | 11,813.33 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 12,815.58 | 13,436.94 | 13,264.22 | 12,524.51 | 11,813.33 |
Other Operating Income | 143.26 | 238.52 | 27.17 | 128.24 | 169.57 |
Other Income | 612.87 | 465.62 | 354 | 532.55 | 605.94 |
Total Income | 13,571.71 | 14,141.08 | 13,645.39 | 13,185.3 | 12,588.84 |
Total Expenditure | 9,604.43 | 9,982.61 | 9,352.43 | 9,045.13 | 9,049.39 |
PBIDT | 3,967.28 | 4,158.47 | 4,292.96 | 4,140.17 | 3,539.45 |
Interest | 49.14 | 51.51 | 69.17 | 61.54 | 73.57 |
PBDT | 3,918.14 | 4,106.96 | 4,223.79 | 4,078.63 | 3,465.88 |
Depreciation | 663.79 | 630.56 | 625.91 | 655.13 | 650.36 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 1,093.71 | 558.86 | 567.21 | 552.25 | 148.93 |
Deferred Tax | 0 | 0 | 0 | 0 | 0 |
Reported Profit After Tax | 2,160.64 | 2,917.54 | 3,030.67 | 2,871.25 | 2,666.59 |
Minority Interest After NP | 4.05 | 9.6 | -2.83 | 24.89 | 4.16 |
Net Profit after Minority Interest | 2,149.88 | 2,903.38 | 3,040.16 | 2,835.62 | 2,654.58 |
Extra-ordinary Items | -240.13 | -265.34 | 0 | 0 | -96.26 |
Adjusted Profit After Extra-ordinary item | 2,390.01 | 3,168.72 | 3,040.16 | 2,835.62 | 2,750.84 |
EPS (Unit Curr.) | 9 | 12.1 | 12.7 | 11.8 | 11.1 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 0 | 1,050 | 0 | 0 | 0 |
Equity | 239.93 | 239.93 | 239.93 | 239.93 | 239.93 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 30.95 | 30.94 | 32.36 | 33.05 | 29.96 |
PBDTM(%) | 30.57 | 30.56 | 31.84 | 32.56 | 29.33 |
PATM(%) | 16.85 | 21.71 | 22.84 | 22.92 | 22.57 |
Both treatments have already received approvals in India and are available for sale there with local partners under a brand known as Tyvalzi and Lyfaquin.
The Board recommended a final dividend of ₹5.50 per share for FY25.
NLC's subsidiary has executed a PPA with Rajasthan Rajya Vidyut Utpadan Nigam Ltd. (RVUNL) for 810 MW solar power plant at Pugal Solar Park, Rajasthan
Based on the Phase 2b clinical trial, the study used a randomised, double-blind, placebo-controlled design that yielded strong and dependable data.
The deal is expected to be completed in the second quarter of 2025, subject to customary closing conditions and regulatory approvals.
An interim dividend of ₹10.50 on the face value per share for FY25 has been declared.
Sun Pharma has bolstered its speciality pipeline with a partnership with Philogen to commercialise late-stage candidate Fibromun.
The US Food and Drug Administration (USFDA) has approved LEQSELVI (deuruxolitinib) 8 mg tablets, according to a regulatory filing.
IMVEXXY is a vaginal insert designed to lessen pain during sexual activity after menopause which is manufactured by Mayne Pharma.
The warning letter detailed substantial violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals at the facility.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
